Table 5.

Mean Percent Change in Primary and Secondary Endpoints per 1 SD Change in RBC Omega-3 Fatty Acids After 6 Months of Treatment

	LVESVI† N = 227	Non-Infarct Myocardial Fibrosis N = 157	Infarct Size† N = 232	LVEF N = 227
Δ Omega-3 Index (% RBC FA) (per 1 SD = 2.6%)	−4.6% (−6.9%, −2.2%) p = 0.0002	−1.0% (−1.9%, −0.1%) p = 0.039	2.5% (−5.7%, 11.3%) p = 0.56	1.1% (0.3%, 1.9%) p = 0.0087
Δ DHA (% RBC FA) (per 1 SD = 1.6%)	−5.2% (−7.5%, −2.8%) p < 0.0001	−1.1% (−2.1%, −0.2%) p = 0.013	1.0% (−7.0%, 9.7%) p = 0.81	1.2% (0.4%, 2.0%) p = 0.0031
Δ EPA (% RBC FA) (per 1 SD = 1.1%)	−3.1% (−5.5%, −0.6%) p = 0.015	−0.5% (−1.5%, 0.4%) p = 0.25	4.4% (−3.9%, 13.4%) p = 0.31	0.7% (−0.1%, 1.5%) p = 0.078

DHA was defined as docosahexaenoic acid, EPA eicosapentaenoic acid, FA fatty acid, LVEF left ventricular ejection fraction, LVESVI left ventricular end-systolic volume index, RBC red blood cell, and SD standard deviation.

^†Natural logarithm transformation was used to improve normality and/or homoscedasticity of residuals.